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ABSTRACT 
 
Background And Objectives : 
 
         Organophosphorous compound poisoning frequently lead to 
respiratory compromise and depend on mechanical ventilation.so,the study 
was conducted to find out the features which support the need of ventilator 
support in these . 
 
METHODS 
 
         All the patients who were diagnosed to have consumed 
organophosphorous compound poison admitted in Chegalpattu Medical 
College Hospital , Chengalpattu. who presented within 24 hours of 
consumption were included in the study. Patients with concomitant 
respiratory illness double poisonings and those treated outside were 
excluded from the study.  
 
RESULTS  
 
          A total number of 100 patients were studied. 60 were males and 40 
were females.36 patients required ventilation. 100% of patients with 
respiratory rate > 25 breaths/ minute and 55% of patients with a 
fasciculation score of ≥4 required ventilation. Ventilation was required by 
84.6% of patients who had a GCS score of ≤ 10.  
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21.7% of patients with mild and 33.3% with moderate poisoning required 
ventilation. In contrast 66.6% of patients with severe poisoning required 
ventilation. Of the patients admitted to the hospital ≥4 hours after 
consumption of poison, 36% required ventilation Of the 19 patients who has 
oxygen saturation levels ≤89%, 18(94.7%) required ventilation.36 patients 
with activation of accessory muscles of respiration need mechanical 
ventilation.During 48 hrs of inpatients administered with maximum dose of 
atropine on mechanical ventilation are compared with non ventilator 
patients. 
Conclusions: 
                      Patients who presented with increased respiratory rate, 
accessory   activation of respiratory muscle, more score of fasciculation 
score, GCS-score of ≤10, increased time delay between consumption of 
poison and admission to hospital (≥4 hours), severe grade of poisoning and 
O2 saturation ≤89% were more likely to require ventilation. The age , sex, 
pulse rate, size of the pupil , and variety of opc product were not correlated 
to the ventilatory support. 
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AIMS AND OBJECTIVES OF THE STUDY: 
 
1. To study the clinical profile of organophosphate compound   
poisoning. 
2. To identify the factors which help in predicting the need  for 
ventilatory support in organophosphorous compound poisoning. 
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INTRODUCTION 
             Organophosphorous compound poisoning is a major health problem 
not only developing countries but also in western countries. Hospital based 
statistics suggest that nearly half of the admission to emergency with acute 
poisoning are due to Organophosphorous compound poisoning. 
 
            Organophosphorous compound were first discovered more than 100 
years ago.organophosphorus compound poisoning are found to be a leading 
cause of deathin agricultural countries globally. Organophosphorous 
compound poisoning affect globally approximately 3 million population and 
cause 2,00,000 deaths annually, most of this occurs in developing countries. 
 
Organophosphorus compounds are easily available as insecticides in 
shops and have resulted in a gradual increase in suicidal and accidental 
poisoning.nearly 90% of the poisoning are suicidal with fatality rate of 
>10%. 8-10 % accidental and <1% homicidal. 
 
 Organophosphorous compounds are the organic derivatives of phosphorus 
containing acids. The phosphonate ,which are organic derivatives of 
phosphoric acid are, not used as insecticides but are used as chemical 
warfare agents. Organophosphorous compounds combine with esteratic sites 
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of acetyl cholinesterase , that is phosphoryllate & phosphorylated esteratic 
sites undergo hydrolysis.the phosphorylated enzyme is inactive and unable 
to hydrolyze acetylcholine. 
 
The biological effects of Organophosphorous compounds are as a 
result of accumulation of endogenous acetylcholine at sites of cholinergic 
transmission. This cause distruption of transmission of nerve impulses in 
both peripheral and central nervous system. Most Organophosphorous 
compounds are readily absorbed through the respiratory, oral mucous 
membrane ,GIT mucous and through the intact skin as they are lipid soluble. 
This  type of binding is irreversible ,except with early pharmacological 
intervention.  
 
The diagnosis is based on the history of exposure and features of 
cholinergic overactivity. The treatment includes atropine or glygopyrrolate , 
which act as a physiological antidode, PAM for reactivating the emzyme. 
complications like respiratory failure , CNS depression & ventricular 
arrhythmias all should be anticipated & treated. 
 
The early cause of death in  Organophosphorous compound poisoning  
are chiefly related to ventricular arrhythmias ,CNS depression ,seizures or 
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respiratory failure occurs due to excessive bronchial secretions, 
bronchospasm, pulmonary edema, gastric contents aspiration , respiratory 
muscles paralysis or apnea associated with depression of the medullary 
respiratory centre. Late mortality is accociated with respiratory failure and 
infection like pneumonia,septicaemia or complications related to 
mechanical ventilator and intensive care management. As atreatmene 
modality for this complication ventilator is required. 
 
This study will help us to identify the factors, which help in 
predicting the need for ventilatory support in a patient with consumption of 
organophosphorus compound. 
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HISTORICAL REVIEW     
Organophosphorous compounds are major group of pesticides used 
worldwide to control insects were identified 100 years ago.These 
compounds exposed to human being either occupations or consumed as 
asucidal agents. 
  More than 35,000 different formulations have come into use as 
pesticides for fast four decades. Of these, organophosphorous are 
predomently used as a insecticide insecticides in world wide. 
Young patients less than 30 years of age are the major victims(9% in 
study). 
  Synthesis of dimethyl & diethyl phosphofluoridates was recorded by 
Lange and krugger in 1932.They are described the symptoms of persistant 
nausea and visual disturbances by this compounds. This observation led 
Schrader of I.G. Farben industries to develop organophosphorous 
compound, first as agricultural insecticides and later as potential chemical 
warfare agents. Finally in Germany, severe compounds are synthesised and 
used as a nitrogen gas, during the worldwar II. 
These compounds used as chemical warfare in 1991, Gulf war.  
            In India first case of Organophosphorous poisoning was reported in 
1962 and first came to India in 1951. 
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CHEMISTRY  
Organophosphorous compounds are usually esters /amides of thiol 
derivatives of phosphoric / phosphonic acids.  
The General formula being:  
            R1      O (or S)  
P ------------------------------X  
                        R2 
Where,  
R1 and R2 are usually simple alkyl or aryl groups. 
                    X is known as the “leaving group” may be one of a wide variety 
of substituted orbranched aliphatic, aromatic or heterocyclic groups linked 
to phosphorous via a bond of some liability usually –O-or -S-.  
                   The double bonded atom may be O or S & the related 
compound, termed a phosphate or phosphorothioate. 7 xxi 
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CLASSIFICATION 
          Holmstedt proposed a classification system for organophosphorous 
that is of pharmacological and toxicological interest. 
The compounds are divided into 5 groups with a few relevant examples.  
Group A: (X: Halogen, Cyanide, and Thiocyanate)  
 E.g.: Disopropylophosphate flourdate (DFP)  
 ISO propyl methyl phosphoflouridate (SARIN)  
 Pinacolyl Methyl phosphoflouridate (SOMAN)  
Group B: (X: Alkyl, alkoxy, aryloxy)  
 E.g.: Forstenon, DDVP, Pyrazoxon  
Group C: (X: Thiol or Thiophosphorous Compound)  
 E.g.: Parathion, Malathion, Azethion, Diazinon, Systox, and Demeton  
Group D: (Pyrophosphates and related compounds)  
 E.g. TEPP, DPDA, OMPA  
Group E: (Quaternary Ammonium Compound)  
 E.g.: Phospholin  
xxii 
An older more commonly used classification divides these compounds into: 
 1) Alkyl phosphates (Eg. TEPP, HETP, OMPA, Malathion, Systox, DFP etc).  
2) Aryl Phosphates (Eg. Demeton, Parathion, EPN,Chlorothion, Diazinon, 
etc).  
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PHARMACODYNAMICS & METABOLISM: 
             These compounds are generally dispersed as aerosols /dusts, 
consisting of organophosphorous compound absorbed to an inert finely 
particulate material. Therefore practically all routes including 
gastrointestinal tract, skin and mucous membranes  
following contact with the liquid form, rapidly and effectively absorb these 
compounds. The lungs also absorb them, after inhalation of the vapours or 
finely dispersed dusts/aerosols. 
              Following absorption they quickly distribute in all tissues, 
maximum concentration usually being reached in the liver and the kidneys. 
Lipophilic compounds may reach high concentration in neural and other 
lipid rich tissues.  
             Plasma half-life ranges from few minutes to few hours, depending 
on the compounds and route of administration. 
             Metabolism occurs primarily by oxidation. Parathion is converted to 
biologically active compound – “Paroxon” by microcosms in the liver.  
            Malathion is metabolized to inactive compound more rapidly in 
higher animals, and consequently is less dangerous to man.  Highly lipid 
soluble agents such as Chlorfenthion may produce symptoms and signs of 
cholinergic over activity for an extended period of days to weeks, caused by 
subcutaneous lipid storage followed by subsequent chronic systemic release 
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after xxvii redistribution. These compounds also cause repeated release after 
apparently successful management.  
        Detoxification of the organophosphorous insecticides occurs, either by 
bio-chemical modification of their structure or by linkage to the binding site 
without toxicological significance.  
        Elimination of organophosphorous compounds and their metabolites 
occur mainly through urine and faeces, with 80-90% of most of compounds 
being eliminated within 48hours.  A very small portion of 
organophosphorous compounds and their active forms are excreted 
unchanged in the urine. Some compounds are known to persist in the body 
for longer periods. xxv 
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MECHANISM OF ACTION 
           Anticholinesterases bind to and inhibit a number of enzymes, yet it is 
their action on the esterase which is of clinical importance.  
            a.nhibition of Acetylcholinesterases (Ach E) Acetylcholinesterases 
(Ach E) are responsible for the hydrolytic cleavage of Acetylcholine (Ach) 
to choline & acetic acid. Acetylcholine is a neurotransmitter for all 
postganglionic autonomic fibers, postganglionic parasympathetic fibers, 
postganglionic sympathetic fibers, neuromuscular junction and some 
interneuron synapses in the CNS. 
        A potential reaction causes release of acetylcholine in the presynaptic 
cleft, most of which is degraded by acetylcholinesterases. Acetylcholine, 
which is not degraded, binds to the postsynaptic receptors resulting in the 
generation of an excitatory postsynaptic potential and propagation of the 
impulse. 
             Anti-acetylcholinesterase has two sites namely, anionic an esteratic 
site. Acetylcholine binds to the anionic site on acetylcholinesterases and 
undergoes hydrolysis in a few seconds. The reversible Anti-
acetylcholinesterases combine with acetylcholinesterases at the anionic site 
and this blocks attachment of the substrate.  
         Irreversible Anti-acetylcholinesterases on the other hand binds to the 
esteratic site of the Acetylcholine and inhibit irreversibly thereby 
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phosphorylating it. This leads to accumulation of acetylcholine at the 
synapses with initial overstimulation followed by inhibition of synaptic 
conduction.  
         Following inhibition, reactivation of the enzyme (acetylcholinesterase) 
occurs at the rate of 1% per day by slow de novo synthesis of fresh enzyme 
and also by spontaneous dephosphorylation. 
           The rate of inactivation (phosphorylation) and reactivation 
(dephosphorylation) depends of the species and the tissue in addition to the 
chemical group attached accounting for the differences in toxicity.  
          Response to reactivating agents decline with time, a process referred 
to as ‘aging’ of the inhibited enzyme. It is a result of loss of an alkyl or 
alkoxyl group leaving a much more stable monoalkyl or monoalkoxyl 
phosphoryl acetylcholinesterase. The aged phosphorylated enzyme      
cannot be reactivated by oximes. In chemical warfare agents  
like so man, aging occurs rapidly.  
b. Neuropathy target esterase inhibition:  
           Neuropathy target esterase inhibition (NTE) followed by its 
transformation to an aged form is responsible for the organophosphate- 
induced delayed neuropathy (OPIDN) . 
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PATHOPHYSIOLOGY  
              Acetylcholine act on the postganglionic parasympathetic ganglia as 
a neurotransmitter. 
                Cholinesterases are divided in to two groups; in red blood cells or 
true cholinesterase and serum pseudocholinesterase. 
              True cholinesterases are seen in nervous tissues and erythrocytes, 
while pseudo cholinesterases  is present in plasma, liver and non-neuronal 
tissues.  
                In case of doubtful opc poisoning pseudocholinesterase levels are 
cremated. 
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CLINICAL FEATURES 
        The clinical manifestations of organophosphorous poisoning can be 
divided in to the following three broad categories: 
1. Muscarinic effects 
2. Nicotinic effects 
3. Central nervous system effects 
  
Muscarinic effects Nicotinic effects Central nervous 
system effects 
CVS MUSCLES  
Bradycardia  Fasciculation  Altered consciousness 
Hypotension  Weakness  Respiratory depression  
 Paralysis  Cheye –stokes 
respiration 
GIT Cramps Dysarthia  
Salivation   Tremors  
Nausea  CVS  
Vomiting  Tachycardia   
Abdominal pain Hypertension   
Diarrhea    
Tenesmus    
Feacal incontinence   
RS   
Brochorrhea    
Wheezing    
Cough    
EYE   
Miosis    
Lacrimation    
Skin -moist   
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The clinical diagnosis is based on:  
      a. history of exposure  
      b. The presence of several of the above symptoms and signs.  
              The time interval between the exposure and onset of symptoms and 
signs varies with the route and degree of exposure. The interval maybe 
within 5 minutes after massive ingestion and is almost always less than 12 
hours. The  manifestation severity varies with the degree of poisoning.  
                Namba et al have made a classification of organophosphorous 
poisoning insecticide which is modified from Grob et al is as follows: -  
Latent poisoning: -  
            No clinical manifestations are seen. Diagnosis based on estimation 
of serumcholinesterase activity, which is inhibited by 10 to 50%  
Mild poisoning: -  
            The patient complains of fatigue, headache, dizziness, nausea, 
vomiting, excessive sweating, salivation, abdominal cramps or diarrhea. 
Serum cholinesterase levels are 20-50% of normal values.  
Moderate poisoning: -  
            The patient complains of generalized weakness, difficulty in talking, 
muscular fasciculations and miosis. Serum cholinesterase levels are 10-20% 
of normal values. 
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Severe poisoning: -  
          Marked miosis, loss of pupillary reflex to light, muscular 
fasciculation, flaccid paralysis, and secretions from the mouth and nose, 
rales in the lungs, respiratory difficulty and cyanosis are seen in patients 
with severe poisoning. Serum cholinesterase levels are 10% lower than of 
normal values.  
The second classification was proposed by Bardin et al12 and is as follows:  
Grade 0             Positive history  
                          No signs of organophosphorous poisoning.  
Grade 1             Mild secretions,  
                          Few fasciculations,  
                          Normal level of sensorium. 
Grade 2             Copious secretions,  
                          Generalized fasciculations,  
                          Rhonchi, crepitations,  
                          Hypotension (systolic BP <90mmHg)  
  Disturbed level of consciousness, not stuperous  
Grade 3            Stupor,  
                         PaO2 < 50mmHg,  
                         Chest roentgenogram abnormal.  
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       This study by Bradin et al showed that on admission  patients with 
grade 3 manifestations need  increased requirement of mechanical 
ventilator. The presence of other complications and increased days of ICU 
stay have been observed in the above patients.  
Following classical op poisoning three well-defined clinical phases are seen: 
 1. Initial acute cholinergic crisis.  
2. The intermediate syndrome  
3. Delayed Polyneuropathy (OPIDN-Organophosphorous   Induced Delayed 
Neuropathy)  
In addition chronic organophosphate induced neuropsychatric disorder  
(COPIND) can occur. 
1. Acute cholinergic phase:  
        This is the initial phase of acute poisoning resulting in muscaranic and 
nicotinic effects. The accumulation of acetylcholine at the muscarnic site 
produces an increase in secretions.  Bronchorrhea,  salivation, sweating, 
bradycardia, vomiting and an increase in gastro-intestinal motility 
(abdominal tightness and cramps). In the eye, organophosphorous agents 
cause the diagnostic miosis which results in blurring of vision. The effects 
of increased acetylcholine at nicotinic sites. Eg: The neuromuscular 
junction, cause muscle fasciculation. Inhibition of acetylcholinesterase in 
the brain leads to headache, insomnia, giddiness, confusion and drowsiness. 
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After severe exposure, slurred speech, convulsions, respiratory depression 
and coma occur. 
            The mechanism of action of paralysis is depolarization and 
desensitization blocks induced by acetylcholine at the neuromuscular 
junctions. Death is likely during thisinitial cholinergic phase due to effects 
on the heart ( bradycardia and other arrhymias), respiration (central or 
peripheral ventilator failure) and on the brain (depression of vital centres). 
Bradycardia may besevere and may progress to heart block. The cholinergic 
phase usually lasts 24 to 48 hours and constitutes a medical emergency that 
required treatment in an ICU. 
  
2. Intermediate syndrome 
            Senanayake and Karallieda first coined the term “Intermediate 
syndrome” in 1987.28 After recovery from the cholinergic crisis, but before 
the expected onset of delayed polyneuropathy, some patients develop a 
muscle paralysis, which is described as Intermediate syndrome. This 
phenomenon has been reported in between 20-68% of the patients.  
            The cardinal feature of this syndrome is muscle weakness affecting 
predominantly the proximal limb muscle and neck flexors. Motor cranial 
nerve palsies (III to VII and X) also occur. Respiratory muscle weakness 
leading to respiratory failure could lead to a fatal outcome. Deep tendon 
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reflexes are usually depressed. The intermediate syndrome occurs after 
recovery from the cholinergic crisis within 24 hours to 96 hours but before 
the expected onset of the delayed neuropathy, which occurs 2 to 3 weeks 
after the poisoning. 
        Complete recovery occurs within 4 to 18 days, if adequate ventilator 
support is provided.  
         The agents commonly responsible are fenthion, monocrotophos, 
dimethoate, diazinon and methyl parathion. 
 
3. Delayed Polyneuropathy  
         The neuropathy develops following latent periods of 2-4 weeks after 
the cholinergiccrisis. The cardinal symptoms are distal muscle weakness, 
calf pain preceding the weakness and in some cases paraesthesia in the 
distal parts of the limbs. Weakness initially appears in the leg muscles 
causing foot drop, followed by small muscles of thehands. Later it may 
extend proximally and even involve the truncal muscles. Deep tendon jerks 
are absent. The prognosis of patients with mild neuropathy is good but those 
with severe neuropathy are usually left with persistent deficits that are claw 
hand, foot drop, persistent atrophy, spasticity and ataxias.  
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          Delayed Polyneuropathy is common following exposure to 
organophosphorous compounds, which have weak anticholinesterase 
activity Eg. Triorthocresylphosphate.  
          The occurrence of Delayed Polyneuropathy appears to follow 
phosphorylaion and subsequent aging of an enzyme in axons called as 
neuropathy target esterase (NTE).  
          The function of this enzyme is not clear yet. It is however present in 
the brain, spinal cord and the peripheral nervous system. NTE is a 
membrane bound protein with high esterase catalytic activity. This 
phosphorylaion enzyme also undergoes ageing. The agents commonly 
responsible are mepafox and chloropyrifos. 
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Chronic Organophosphate Induced Neuropsychiatric Disorder 
(COPIND) 
1.Chronic op –induced neuropsychiatric disorder (COPIND) is a condition 
characterized by a prolonged exposure to op pesticides(with or without 
acute cholinergic episodes) and the development of various neuropsychiatric 
symptoms. 
2. Follow up studies of individuals who were exposed to high levels of the 
op compound have shown an emergence of certain similar types of 
neurobehavioral changes, which has been termed together as COPIND. 
3. The neurobehavioral changes include anxiety, mood swings, emotional 
lability, depression, fatigue, irritability ,drowsiness, confusion and lethargy. 
     Recent studies suggest that Parkinson’s disease is a more common in 
patients who report to have had previous exposure to pesticides. 
 
Other effects of organophosphorous intoxication  
 Altered immunity to infection  
          In 1974, Bellin and Chow 37suggested that organophosphorous 
agents might have an effect on the human immune system. Casali et al38 
demonstrated that parathion suppressed both the primary IgM and IgG 
response to sheep erythrocytes in mice.  
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Newcombe39 showed an increased incidence of lymphoproliferative 
disorders associated with impaired natural killer cell and cytotoxic T-cell 
function. 
Murray et al40 reported influenza like symptoms in 23 patients after 
occupational exposure to organophosphorous compounds.  
Changes in metabolism and endocrine activity 
           In animal experiments, changes in the diurnal pattern of plasma 
ACTH have been reported following organophosphorous poisoning. 
41Nicotinic receptors also function in brain pathway that increases the 
release of several pituitary hormones including vasopressors, ACTH and 
prolactin. In man, nonketotic hyperglycemia may occur. 
Effects on the CVS  
        Kiss and Fazekas44 reported QT prolongation along with ST segment, 
T-wave anomalies and other forms of arrhythmias. Recurrent ventricular 
tachycardia with the torsade de pointis phenomenon was seen. 
Complete atrioventricular block may occur. 
         QTc prolongation indicates a poor prognosis and a higher incidence of 
respiratory failure. 
Effects on Reproduction 
         There is a report of termination of pregnancy following 
organophosphorous poisoning during the first trimester. In experimental 
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animals, organophosphorous poisoning during pregnancy cause pre- and 
postnatal death and congenital abnormalities such asvertebral deformities, 
limb defect, polydactyl and cleft palate. 
GI effects  
         Profuse diarrhea for 2 to 5 day’s after ingestion of organophosphorous 
insecticides has been reported. 
Temperature Regulation 
         After exposure to most organophosphorous compounds, a marked 
hypothermia response lasting upto 24 hours has been demonstrated. 
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DIAGNOSIS 
Diagnosis depends on the following factors: 
a. History or evidence of exposure to anticholineserase agents.  
b. Signs and symptoms of poisoning.  
c. Improvement of these clinical features with atropine and    PAM.  
d. Inhibition of cholinesterase activity.  
            In most patients, a history of exposure to organophosphorous 
insecticide can be obtained. A container is usually found. History may be 
denied in attempts of suicide or unavailable  in-patients who are found 
unconscious. Organophosphates impart a garlic-like odour to the breath, 
vomitus or faeces. 
            The signs of organophosphorous poisoning that are most helpful in 
diagnosis are miosis and muscle fasciculation’s.  
            Others include excessive perspiration, salivation, Lacrimation and 
bronchial secretion. 
          The response to atropine therapy may also be useful aid to diagnosis, 
with patients who have organophosphorous poisoning showing a tolerance 
to atropine. There is also failure to produce signs of atropinisation with1 to 
2mg of atropine administered intravenously. Inhibition of cholinesterase 
activity of the blood is also helpful. Estimation of erythrocyte cholinesterase 
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(acetyl cholinesterase) is theoretically preferred as it reflects the degree of 
inhibition of synaptic cholinesterase.  
         However, estimation of plasma cholinesterase (pseudo cholinesterase) 
can be done.Methods used for assay for AchE activity vary in 
sophistication. They include the classical electrometric method, the 
calorimetric method and a Titrometric assay.  
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TREATMENT 
All patients should be managed as emergencies in hospital.  
A. Acute Cholinergic Crisis:  
 Treatment is based on the following principles:  
a. Minimizing further absorption of the insecticide. 
b. Pharmacologically countering the effects of the poison.  
c. Maintaining vital functions.  
       Successful management requires rapid and simultaneous 
implementation of the above principles.  
        First aid measures should include removal of patient from the 
contaminated environment,removal of contaminated clothes and washing of 
the skin and eyes. 
        Respiratory failure is the usual cause of death in the acute phase; 
resuscitation and artificial respiration may be required immediately. Mouth-
to-mouth respiration should not be attempted. Various degree of heart block 
include cardiac arrhythmias also should be managed accordingly. 
        Gastric lavage is most effective within 30 minutes of ingestion but is 
advised also at the time of admission after taking necessary precautions to 
protect the airway. If the patient  is semiconscious/unconscious Ryle’s tube 
aspiration can be done. Activated charcoal may be administered to reduce 
further absorption from the stomach.  
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Atropine: 
         Treatment with anticholinergic medication is still the mainstay of 
treatment and should be started as soon as the airway has been secure.  
         These agents act as a competitive antagonists at the muscarinic 
cholinergic receptors in both the central and the peripheral nervous system. 
These agents do not treat nicotinic effects. 
            A recommended dose is 2-4 mg intravenous, repeated at interval of 
5-10 minutes initially and continued until signs of atropinisation (dry 
mucous membrane, dilated pupils, flushing of skin and a heart rate of > 100 
beats/ minute) appear. Atropine therapy should be maintained until there is 
complete recovery.  
            Infusion of atropine are used in some centers in dose of 0.02-0.08 
mg/kg/hr.51 Infusion of atropine has produced significant reduction in 
mortality in some centers when compared to conventionally intermittent 
therapy. A heart rate exceeding 140 beats/minute should be avoided. ST-
segment abnormalities in the ECG may be induced by large doses of  
atropine. These may be corrected with propronalol, eliminating any need to 
reduce the rate of administration of atropine. Atropine crosses the blood 
brain barrier and may cause  severe toxic effects such as convulsions, 
psychosis and coma. 
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Glycopyrrolate:  
This is a quaternary ammonium compound can be used as an 
alternative to atropine. 
The advantages of Glycopyrrolate over atropine are: -  
a. Better control of secretions . 
b. Mild tachycardia. 
c. Few CNS side effects. 
Oximes:  
         The observation that oximes reactivates phosphorylated AchE more 
rapidly than spontaneous hydrolysis led to the development of Pralidoxime 
(Pyridine-2-aldoxime methyl chloride, PAM) and later Obidoxime. 
           Pralidoxime is act on skeletal neuromuscular junction through 
reactivated the inhibited phosphorylated enzyme. It is administred 1 gm 8 
hourly given intravenous in 250ml normal saline over 30 minutes. It has no 
effect on the muscarinic effect on muscarinic receptor. Intravenous route, it 
has very slow half life of 1.2hrs and never cross the BBB. 
           PAM was given immediately with in 43 hrs, as regeneration of AchE. 
Aging of the enzyme has depend on the life span of erythrocytes. 
            PAM is available as the chloride iodide, mesylate and methyl sulfate 
salts. The chloride salt is more stable than iodide in dry state and is 
preferred for intramuscular use. 
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           The major pharmacological action of oximes is to reactivate AchE by 
removal of phosphate group bound to the esteritic site. This action occurs 
shortly after poisoning and inhibition of the enzymes, after which the 
enzyme ages and becomes more firmly bound to esteratic site. Oximes 
should be given as soon as possible before aging takes place. They are 
effective if given within 6 hours of poisoning upto 24 hours of poisoning but 
good response seen in within 6 hrs. 
         The therapeutic effects of oximes seemed to depend on the plasma 
concentrations of the organophosphorous agent with the benefit being, 
minimal at high concentrations of organophosphorous in the blood. 
Pralidoxime does not cross the blood-brain barrier whereas obidoxime does.  
       Paradoxically neuromuscular block and inhibition of AchE is seen in 
overdose of atropine and obidoxime. 
       Atropine and Obidoxime produce a cumulative effects of cardiac 
arrhythmias in most of the patients. 
Diazepam: 
           Some reports have indicated that benzodiazepines are useful as 
antidotes in poisoning by anticholinesterases. This appears  to counteract 
some aspects of CNS derived symptoms and also increase therapeutic 
benifits of atropine and PAM.  
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Diazepam is given to control seizures and to induce sedation during 
mechanical ventilation.  
Fluoride:   
          Fluoride and atropine combination produces a greater antidote effect 
than atropine alone.  
          It was noted that increased cholinesterase levels were observed in 
workers in a plastic factory handling fluoride compounds.  
Magnesium: 
        Kiss and Fazekas44 reported that ventricular premature contractions 
were successfully eliminated with intravenous magnesium sulfate. The 
magnesium was thought to counteract direct toxic inhibitory effect of 
organophosphates on sodium-potassium ATPase.  
Phenothiazines: 
          The use of phenothiazines in the management of organophosphorous 
poisoning is controversial. Diazepam has proved to be satisfactory and 
popular alternative. 
Respiratory stimulants:  
          Respiratory stimulants should not be used in the treatment of 
organophosphorous poisoning in humans, particularly, in view of the 
bronchospasm, neuromuscular block and convulsions that are associated 
with intoxication. 
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Other measures:  
             Hemodialysis against activated charcoal is effective in demeton-S-
methyl sulphoxide; dimethoate and parathion poisoning. Injection of human 
cholinesterase also improve the condition of the patients was reported. 
Using of corticosteroids and camphor need further evaluation in future. 
Management of Intermediate Syndrome:  
1.Ventilatior support: 
Patient with intermediate syndrome often lead to respiratory muscle      
weakness need   mechanical ventilation. 
2.Benzodiazepines are useful in sedating the anxiety patients with ventilator. 
3.correction of electrolyte imbalance through ABG analysis. 
 Management of Delayed Neuropathy:  
       No specific drug therapy has proved useful. The muscle weakness 
benefits from regular exercise and physiotherapy.  
xlv 
Complications  
43% of patients with OPC poisoning developed complications due to 
large amount of consumption and increased level of absorption. 
Early deaths are due to Respiratiry depression, seizures, and 
ventricular arrhythmias (Eg. Torsade de pointes) or respiratory failure due to 
excessive bronchial secretions. 
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Late mortality is caused by respiratory failure  associated with infection 
(pneumonia, septicemia) or ventilator related complications.  
There are various studies in which respiratory failure was the 
commonest complication encountered following acute organophosphorous 
poisoning.  
         Aspiration, oropharengeal and airway secretions,pulmonary 
infections,consolidation,sepsis and ARDS are attributed to the pathogenesis. 
       Secretion and constriction of airways and laryngeal spasm are due to 
muscuranic  stimulations leads to respiratory failure.These effects associated 
with respiratory muscle weakness and paralysis is caused by nicotinic 
effects. 
          In the initial period of poisoning respiratory centre of the brainstem 
synapses are over stimulated by cholinergic activity cause respiratory failure 
and death. 
           In the  later stage, respiratory muscle weakness and paralysis due to 
peripheral neuromuscular blockad and intermediate syndrome are the main 
cause of respiratory failure. Unsuspected or incipient respiratory failure 
associated with sudden cardiovascular collapse belongs to higher mortality.  
             Upto 43% of the patients has developed pneumonia in the delayed 
cause of respiratory failure. Upto 80% of patients with pneumonia had 
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respiratory failure;  within 96 hours 80% of patients with pneumonia had 
developed respiratory insufficiency. 
             Inadequate or delayed atropinisation appears to be one of the 
principle reasons for the development of pneumonia12 and emphasis the 
importance of skilled medical assessment and treatment at an early stage 
after poisoning.  
 
Prevention: 7 
         Preventive measures should be considered at all the levels of the chain 
of insecticide movement through the environment-formulation manufacture, 
mixing application and disposal.  
         Guidelines for prevention of contamination of food and other utilities. 
Psychiatric  counselling for the patients who consumed OPC poisoning. 
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METHODOLOGY  
 
         The study was conducted on 50 patients who were diagnosed to have 
consumed organophosphorous compound poison admitted in R.L.Jalappa 
Hospital and Sri Narasimha Raja District Hospital who were admitted 
within 24 hours of consumption of the poison. The included patients were 
intensively monitored for signs of respiratory insufficiencies like respiratory 
rate of > 30 breaths/minute, accessory muscles of respiration in action, O2 
saturation< 90%, Arterial Blood Gas Analysis (ABG)- PaO2 < 50 mmHg, 
PCO2 > 50 mmHg. If any one or more are present, the decision for 
mechanical ventilator was taken. Bradycardia was defined as < 60 
beats/minute.  
         Patients accompanying with other respiratory disorders; those 
comsuming opc with other poisoning chronic lung disease and those who 
treated other hospitals were not taken in the study. 
          Based on the factors that influence the need for ventilatory support, 
the severity of organophosphorous compound poisoning was graded as 
mild, moderate and severepoisoning. 
Mild Poisoning includes  
♦ Normal level of consciousness (score of 12-15 by Glasgow coma scale 
(GCS)).  
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♦ Pupil size ≥ 4mm. 
♦ Fasciculation score 0-1.  
Moderate Poisoning includes  
♦ Mild alteration in level of consciousness (score of 8-11 by GCS).  
♦ Pupil size 2-3mm. 
♦ Fasciculation score 2-4.  
Severe poisoning includes  
♦ Stupor / Coma (score of 7 or less by GCS). 
 ♦ Pin point pupil (1mm or less)  
♦ Presence of convulsions  
♦ Fasciculation score 5 or more.  
♦ Signs of respiratory insufficiency.  
         Fasciculations of anterior chest, posterior chest, anterior abdomen, 
posterior abdomen, right thigh, left thigh, right leg, left leg, right arm and 
left arm was given one point for each area. Then grading of  Fasciculation 
score was estimated. 
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RESULTS AND OBSERVATION 
            100 patients diagnosed to have consumed organophosphorous 
compound poison were studied in relationship to the need for ventilatory 
support. In the total target study of 100 patients, 36 patients required 
ventilatory support.  
                                                     Table 1  
                               Age distribution with ventilation 
 
Age in years 
(n=100) 
Number of 
patients 
presented 
Number of 
patient with 
ventilation 
P Value Odds ratio 
(ventilation) 
13-20 22  (22%) 8 (8%) p>0.05 1.02 
21-30 58 (58%) 22 (22%) 0.738 1.22 
>30 20 (20%) 6 (6%) 0.730 0.71 
 
Figure-1 
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Result: Majority of the patients who were ventilated were in the age group 
of 21-30(58%) but this was not statistically significant (P>0.05).  
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Table 2 
Sex distribution with ventilation  
 
Sex Number of patients 
Presented 
(n=100) 
P value 
Male 60 
(60%) 
P=0.186 
Female 40 
(40%) 
P=0.186 
  
Figure 2 
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Results: 
            Male patients were 30(60%) and females were 20(40%). The gender 
distribution among patients ventilated is not statistically significant with sex 
(P>0.05).  
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Table 3  
Relationship of Compounds consumed with ventilation 
 Compounds 
(n=100) 
Number of 
patients 
presented 
Number of 
patients with 
ventilated 
P value Odds Ratio 
(ventilation) 
A Betanechol  8 (8%) - - - 
B Chlorpyrifos 2 (2%) - - - 
C Cypermethrine 2 (2%) - - - 
D Diazinon 2 (2%) - - - 
E Dimethoate 26 (26%) 14 (14%) 0.180 2.75 
F Meta 
dimethoateid  
2 (2%) 2 (2%) 0.360 - 
G Methyl parathion 26 (26%) 14 (14%) 0.180 2.75 
H Monocrophsos 16  (16%) 4 (4%) 0.694 0.54 
I Quinophos  4 (4%) - - - 
J Triazophos  10 (10%) 2 (2%) 0.642 0.40 
K Volphor  2 (2%) - - - 
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Figure 3 
 
 
Results:  
Of the patients who consumed organophosphorous poison, 
dimethoate and methyl parathion were the most commonly consumed 
poisons (13 in each group). 54% patients who consumed these compounds 
required ventilatory support. Patients who consumed Monocrophos and 
Triazophos were least likely to receive ventilatory support. Hence, 
statistically patients who consumed dimethoate and methyl parathion are 
2.75 times more likely to receive ventilation. lv 
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Table 4  
Relationship of fasciculation score with ventilation  
 
Fasciculation 
score(n=100) 
Number of 
patients 
present 
Number of 
patients with 
ventilation 
P value Odds ratio 
(ventilation) 
0 28 (28%) 6 (6%) 0.181 0.38 
1-3 40 (40%) 10 (10%) 0.186 0.44 
>4 32 (32%) 20 (20%) 0.007 5.42 
 
Figure 4 
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Results:  
      Generalised fasciculations was another conspicuous feature in 72% of 
cases in this study.Patients with fasciculation score of ≤ 3 are less likely to 
receive ventilation. The patients with a fasciculation score ≥4 are 5.42 times 
more likely to receive ventilation. 
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Table 5  
Relationship of pupil size with ventilation  
 
Pupil size 
(n=100) 
Numbers of 
patients 
presented 
Number of 
patients with 
ventilation 
P value Odds ratio 
(ventilation) 
≤1 28  (28%) 20 (20%) 0.423 1.61 
≥2 52 (52%) 16  (16%) 0.423 0.62 
 
Figure 5 
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Results:  
       Patients with pupil size ≤ 1 mm are 1.61 times more likely to require 
ventilation as compared to the patients with pupil size ≥ 2 mm. This finding 
is not statistically significant. 
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                                        Table 6  
                         Relationship of GCS-score with ventilation  
GCS -score Number of 
patients 
presented 
Number of 
patients with 
ventilation 
P value Odds Ratio 
(Ventilation) 
≤10 26 (26%) 22 (22%) P<0.001** 23.57 
11-15 74 (74%) 14 (14%) P<0.001** 0.04 
Figure 6 
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Results:  
           Thirty seven (74%) patients had a GCS- score of 11-15, out of these 
7(18.9%) patients required ventilatory support.Ventilatory support was 
required by 84.6% of patients who had a GCS score ≤10. Hence, patients 
with GCS-score ≤10 are 23.57 times more likely to receive ventilation when 
compared to the patients with GCS-score 11-15. 
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Table 7 
            Requirement of ventilatory support in relation to severity of 
organophosphorous compound poisoning 
Type of 
poisoning 
(n=100) 
Number of 
patients 
presented 
Number of 
patient with 
ventilation 
P value Odds Ratio 
(ventilation) 
Mild 
 
46 (46%) 10  (10%) 0.050 0.30 
Moderate 30 (30%) 10 (10%) 0.797 0.85 
Severe 24 (24%) 16 (16%) 0.01 5.60 
Figure 7 
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Results:  
Five (21.7%) of the patients with mild poisoning and 33.3% of the 
patients with moderatepoisoning required ventilatory support. In contrast 
66.6% of the patients with severe poisoning required ventilation. Hence, 
patients with severe poisoning were 5.6 timesmore likely to receive 
ventilation.  
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Table 8 
 
                Relationship between time lag of consumption of poison and 
admission to the hospital with ventilatory support  
  
Time lag Number of patients 
Presented 
Number patients with 
ventilation 
<4 hrs 4  (4%) - 
≥4 hrs 96  (96%) 36 (36%) 
                                           
Figure 8 
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Results:  
        Of the patients admitted to the hospital ≥4 hours after consumption of 
poison, 36% required ventilatory support. In comparison, patients admitted 
< 4 hours of consumption did not require ventilatory support. This finding is 
statistically significant. 
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Table 9 
Relationship of pulse rate with ventilation  
 
Pulse rate 
(n=100) 
Number of 
patients 
presented 
Number of 
patients with 
ventilation 
Significance 
(p value) 
≤60 6 (6%) 2 (2%) p>0.05 
61-70 62 (62%) 26 (26%) 0.264 
≥20 32 (32%) 8 (8%) 0.266 
Figure 9 
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Results:  
             Bradycardia was present in 6% of the cases in the present study. 
There is no statistical association between pulse rate and ventilation.  
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Table 10 
Relationship of respiratory rate with ventilation 
Respiratory 
rate 
(n=100) 
Breath/min 
Number of 
patients 
presented 
Number of 
patients with 
ventilation 
P value Odds ratio 
(ventilation) 
≤20 60 (60%) 6 (6%) P<0.001 0.04 
21-25 16 (16%) 6 (6%) p>0.05 1.08 
26-30 18  (18%) 18 (18%) P<0.001 - 
>30 6  (6%) 6 (6%) 0.042 - 
                                           Figure 10  
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Results:  
100% of the patients with respiratory rate >25 breaths/minute required 
ventilatory support, which is statistically significant with a P value <0.001.  
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Table 11  
Relationship of O2 saturation with ventilation  
 
O2 Saturation 
(n=100) 
Number of patients 
presented 
Number of patients 
with ventilation 
90-100% 62 (62%) - 
≤89% 38  (38%) 36 (36%) 
 
                                             Figure 11  
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Result:  
 
           Of the 19 patients who had oxygen saturation levels of ≤89%, 
(94.73%) required ventilatory support. 
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Table 12 
Relationship of the use of accessory muscles with ventilatory support  
 
Accessory 
muscles 
Number of patients 
Presented 
Number of patients 
With ventilation 
Not- acting 64  (64%) - 
In action 36 (36%) 36 (36%) 
 
                                    Figure 12  
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Results:  
         Eighteen (38%) patients had accessory muscles of respiration in 
action, of which all required ventilatory support. This is statistically 
significant. 
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Table 13  
 
Relationship of atropine dose within 
48 hours of admission with ventilatory 
support  
 
Atropine dose(mg) within 48 hrs 
 
Number of            
patients 
Mean ±SD 
Ventilated  
 
36 161.33±64.31 
Not ventilated 
 
64 100.93±93.12 
Significance student t             Student t=3.971 
                 P=0.00239 
  
                                        Figure 13  
 
0
50
100
150
200
250
ventilated not ventilated
Column1
Column2
 
Results:  
      Patients who were ventilated required a higher dose of atropine within 
48 hours of admission as compared to those who were not ventilated. This is 
statistically significant. 
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Table 14  
Factors predicting the need for ventilatory support 
Factors No. of 
patients 
ventilated 
No. of 
patients  
not 
ventilated 
P values Odds ratio 
(ventilation)  
 
Dimethoate  14(14%) 12(12%) 0.180 2.75 
Methyl parathion     14(14%) 12(12%) 0.180 2.75 
Fasciculation  16(16%) 52(52%) 0.007 0.18 
Pupil size (≤1mm)  20(20%) 28(28%) 0.423 1.60 
Pupil size (≥2mm)  16(16%) 36(36%) 0.423 0.62 
GSC-scale (≤10  22(22%) 4(4%) P<0.001** 23.57 
GCS-score11-15  14(14%) 60(60%) P<0.001** 0.04 
Mild Poisoning  10(10%) 36(36%) * 0.050 * 0.30  
Mod. Poisoning  10(10%) 20(20%) 0.797 0.85 
Severe Poisoning  16(16%) 8(8%) 0.01* 5.60 
Time lag (< 4 hrs)  - 4(4%) P<0.001 - 
Time lag ((≥4 hrs)  - 60(60%) P<0.001** - 
Pulse rate 
(≤60beats/min)  
2(2%) 4(4%) P>0.05  
0.88 
Pulse rate (≥ 
61beats/min) - 
34 (34%)  
 
60(60%) P>0.05 1.13 
 
Respiratory rate (≤ 
25breaths/min)  
12(12%) 64(64%) P<0.001** - 
Respirator(> 25 
breaths/min)  
24(24%) - P<0.001** - 
O2 Saturation 
(≤89%)  
36(36%) 2(2%) P<0.001** - 
O2 Saturation (≥90)  - 62(62%) P<0.001** - 
Accessory muscles-
inaction  
- 64(64%) P<0.001** - 
Accessory muscles-
not in action  
18 (36%) - P<0.001** - 
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STATISTICAL METHODS 
          Chi-square test and Fisher Exact test has been used to find the 
significance of ventilation requirement for all the study parameters. The 
Odds ratio has been used to find the strength of relationship between the 
ventilation requirement and the each study parameters. Analysis of variance 
has been used to find the significance change of study parameters in mild, 
moderate and severe type of poisoning. The Kruskal walis test has been 
used to find the significance change of GCS –score in mild, moderate and 
severe type of patients, as the GCS-score do not follow normal distribution. 
Student t test has been used to find the significance of mean difference 
atropine with in 48 hours between ventilated and not ventilated patients. 
 
Statistical software  
         The Statistical software namely SPSS 10.0 and Systat 8.0 were used 
for the analysis of the data and Microsoft word and Excel have been used to 
generate graphs, tables etc. 
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DISCUSSION 
           Acute Organophosphorous compound poisoning is one of the most 
frequent poisonings encountered in RLJH.  
           The major cause of poisoning in the present study was attempted 
suicides (100%).Suicide is the major cause of poisoning in developing 
countries. In contrast, figures from developed countries like Japan, show 
accidental exposure forms a major bulk of organophosphorous compound 
poisoning cases.  
           Among the 100 cases studied, majorities of the patients were in the 
age group of 21-30 years (58%). This correlates with the study done by 
S.Singh et al. 
           In the present study, 60% of the patients were males. This correlates 
with the findings of theprevious studies. However, in a study done by M. 
Vishwanathan et al69, 66% of the patients who consumed 
organophosphorous compound were females.  
           Vomiting was the most common symptom in 80% of the patients in 
this study. This correlates with the studies done by OP Gupta et al, Sarjit 
Singh et al, and, Goel et al64 where vomiting was present in 90% and 
97.08% of the cases respectively. Vomiting was probably due to chemical 
gastritis.  
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           Generalised fasciculations was another conspicuous feature in 72% 
of cases in this study. Whereas, studies done by Goel et al and Sarjit Singh 
et al showed that 55% and 100% of the patients respectively had 
fasciculations.  
            
        Twenty four (28%) patients had pupil size ≤ 1 mm of which 10 
(41.6%) patients required ventilatory support. According to the study done 
by OP Gupta et al70 28% had pupil size ≤ 1 mm who required ventilatory 
support. In comparison, in a study done by Robert et al72 73% who had 
pupil size ≤ 1mm required ventilation.Bradycardia at admission was present 
in 6% of the cases in the present study. In comparison, in a study done by 
Robert et al 19% of the patients had bradycardia, while in a study carried 
out bySemir Nouria, 17% had bradycardia. This has not been compared with 
the need for ventilation. Twelve (24%) patients had respiratory rate >25 
breaths/min of which all patients required ventilatory support. The higher 
respiratory rate was probably due to increased secretion and more severe 
respiratory paralysis caused by the poison itself. According to the study 
done by G. S. Mutalik et al 40% of the patients had a respiratory rate more 
than 30 breaths/min but this has not been compared with the need for 
ventilation. 
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             Nineteen (38%) patients had oxygen saturation levels of ≤ 89% out 
of which 18(94.73%) patients required ventilatory support. Eighteen (36%) 
patients had accessory muscles of respiration in action, of which, all 
required ventilation. There are no comparative studies available.  
              It was observed in this study that 36% of the patient with 
respiratory failure required mechanical ventilation as compared to 40% of 
the patients in a study done by T.C.Tsao et al.11 Arterial blood gas analysis 
was done in 36 patients who had a respiratory rate > 25 breaths/minute and 
whose accessory muscles of respiration were in action. All of them had 
respiratory acidosis.  
         Patients who were ventilated required a higher dose of atropine within 
48 hours of admission as compared to those who were not ventilated. This 
was consistent with the findings of the study done by Goel et al.64 Higher 
dose of atropine may indirectly indicate the severity of poisoning which 
might have caused respiratory paralysis requiring ventilation.  
           The severity of organophosphorous compound poisoning and the 
need for ventilatory support was studied in relationship to the nature of 
compounds consumed. 53.64% of the patients who consumed Dimethoate 
and 53.64% of the patients who consumed methyl parathion required 
ventilation in this study. Whereas, in the study done by Goel et al64, 
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66.67% of the cases who had consumed Dimethoate was associated with 
maximum need for ventilatory support.  
         Ventilatory support was required by 84.6% of patients who had a GCS 
score level of less than 10.This correlates very well with the study done by 
Goel et al, where 84% of the patients with GCS- score less than 10 required 
ventilation.  Of the patients with fasciculation score ≥ 4 required ventilatory 
support in our study whereas in a study done by Goel et al64, 55% of the 
patients with a fasciculation score of more than or equal to 4 required 
ventilatory support.  
             21.7% of the patients with mild poisoning and 33.3% of the patients 
with moderate poisoning required ventilatory support. In contrast 66.6% of 
the patients with severe poisoning required ventilation. Studies done by 
Goel et al64 have shown that about 4% of the patients with mild and 6% of 
patients with moderate poisoning required ventilator support whereas 62% 
of the patients with severe poisoning required ventilatory support. The 
reason for greater percentage of patients requiring ventilation in mild 
poisoning group in our study is likely to be due to the greater time lag 
between poison consumption and to admission at the hospital. 
         This in turn resulted in delay in treatment, like initiation of gastric 
lavage and administration of atropine and PAM.  
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       Of the patients who were admitted to the hospital after 4 hours or more, 
after consumption of organophosphorous poison, 36% required ventilator 
support, as compared to those who were admitted within < 4 hours of 
consumption..The studies done by Goel et al and S.S.Kumar et al which 
indicated a very significant relationship between delay in treatment and 
need for ventilator support. In contrast, a study done by Karnik et al found 
this delay statistically insignificant.  
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CONCLUSIONS 
          The factors, which predicted the need for ventilatory support in 
organophosphorous compounds poisoning in our study of 100 patients, were 
as follows:  
1. The presence of higher fasciculation score (≥ 4) was associated with the 
higher need for ventilatory support. 
 2. A GCS score ≤10 was significantly associated with an increased need of 
ventilatory support.  
3. Greater time lag between consumption of poison and admission to 
hospital (≥ 4 hours) was associated with higher need for ventilator support. 
 4. Higher respiratory rate (>25 breaths/minute) and accessory muscles of 
respiration in action was significantly associated with higher need for 
ventilator support.  
5. O2 saturation of ≤ 89 mmHg was significantly associated with higher 
need for ventilatory support.  
6. Grade 3 severity of poisoning was associated with higher need for 
ventilator support.  
7. Dose of atropine greater than 150 mg within 48 hours of admission was 
associated with higher need for ventilatory support. 
8. The relationship between age group and sex with ventilatory support was 
not found to be significant. 
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9. Size of the pupil and pulse rate, type of organophosphorous compound 
consumed had no relevance in predicting the need for ventilatory support. 
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SUMMARY 
Organophosphorous compound poisoning has been a continuing 
scourge in both developing and developed countries alike. Rampant misuse 
of organophosphorous compounds have been found in the predominantly 
rural agrarian societies, where such compounds are used as fertilizers. It is 
in this background that a study was undertaken in the Chengalpattu Medical 
College Hospital, Chengalpattu. in a sample of 100 patients who had 
consumed organophosphorous compounds. Some of these patients 
developed respiratory failure requiring ventilation resulting in more 
morbidity, mortality, cost and duration of stay in hospital. The basic 
objective of the study was to identify factors that help in predicting the need 
for ventilatory support in these patients. Patients with concomitant 
respiratory illness, double poisonings and those treated outside were 
excluded from the study. 
         The clinical manifestations of organophosphorous compound 
poisoning are due to cholinergic over activity and can be divided into 
muscarinic-like, nicotinic-like and the effects on the CNS. Typically three 
well-defined clinical phases are observed following the poisoning. They are 
a. the initial acute cholinergic crisis, b. intermediate syndrome and c. 
delayed polyneuropathy. Diagnosis of organophosphorous compound 
poisoning is based on the history of exposure and features of cholinergic 
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over activity. Treatment for this includes gastric lavage, administration of 
atropine and PAM that act as physiological antidotes.  
The most common symptom manifested in our study was vomiting. 
The signs observed in the patients were generalized fasciculations, 
bradycardia, and tachypnoea. This studyfound that 60% of the patients were 
males. Patients with moderate and severe poisoning required higher doses of 
atropine as compared to those with mild poisoning. 38 patients had oxygen 
saturation levels of ≤ 89% out of which 36 patients required ventilatory 
support.  
          In this study it was found that patients who had consumed Dimethoate 
and Methyl parathion showed an increased requirement for ventilatory 
support. 
           On application of the parameters of GCS Score and fasciculation 
score as a criterion topredict ventilatory support, it can be inferred from the 
study that 14% of patients with GCS score between 11-15 required 
ventilation, where as 74% of patients in who had a GCS score of ≤ 10 
required ventilation.  
           Sixty two percent (62%) of the patients with a fasciculation score of 
≥ 4 required ventilation. Patients who were admitted to the hospital, ≥ 4 
hours after consumption of poison, required ventilatory support. 
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           After analyzing the data of the study we could conclude that patients 
who presented with higher respiratory rate (>25 breaths/min), accessory 
muscles of respiration in action,higher fasciculation score, GCS-score of 
≤10, greater time lag between consumption of poison and admission to 
hospital (≥4 hours), severe grade of poisoning and O2 saturation ≤89% were 
more likely to require ventilation. There is no relationship between age 
group, sex, pulse rate, pupil size, and type of organophosphorous compound 
consumed with the need for ventilation. 
  
 
73 
 
BIBLIOGRAPHY 
1. Peter JV, Cherian AM. Organic insecticides. Anaesthesia   and intensive 
care2000; 28 (1) : 11-21 
2. Singh S, Sharma N. Neurological syndromes following organophospate 
poisoning. Neurology India 2000 ; 48 (4) : 308-13. 
3. Singh S, Wig N, Chaudhary D et al : Changing pattern of acute poisoning 
in adults : experience of a large north west Indian hospital (1970-1989). 
JAPI 1997 ; 45 : 194-197.  
4. Malik GM, Mubarik M, Romshoo GJ: Organophosporous poisoning in 
the Kashmir valley 1994 to 1997. NEJM 1998 ; 338: 1078-1079  
5. Philip G. Bardin. Organophosphorous and carbamate poisoning. 
Archieves ofinternal medicine 1994; 154 : 1433-1441  
6. Ferrando F. Pesticide poisoning in the Asia-Pacific region and the role of 
a regional information network. Clinical toxicology 1995; 33 : 677-682.  
7. Karalliedde L, Senanayake N : Organophosporous insecticide poisoning. 
British Journal of anaeasthesia 1989; 63; 736-750.  
8. Koelle GB. Pharmacology and toxicology of organophosphorous and 
carbamates. In: clinical and experimental toxicology of organophorphates 
and carbamates. Ballantyn B, Marrs T, eds. Butterworth Hunmann, Oxford 
1992; 33-37.  
74 
 
 
9. Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to 
organophosphorous insecticide. American Journal of Medicine 1971; 50 : 
475-492.  
10. Steward WC, Anderson Ea. Effects of cholinesterase inhibition when 
injected into the medulla of the rabbit. Journal of Pharmacological 
Experimental Therapy 1968;162: 309-317.  
11. Tsao TC, Jwang Y, Lan R, Sheieh W, Lee C. Respiratory failure in 
acute organophosphorous and carbamate poisoning. Chest 1990; 98 : 631-
636.  
13. Bardin PG, Van Eeden SF. organophosphorous poisoning: grading the 
severity and comparing treatment between atropine and glycopyrolate. 
Critical care Medicine 1990; 18 : 956-960. 
 14. Davies JE. Changing profile of pesticide poisoning. NEJM 1987; 316 : 
807-808. 
 15. Karalliedde L, Senanayake N. Acute organophosphorous insecticide 
poisoning in Sri Lanka. Forensic Science International 1988; 36: 97-100 
. 16. Taylor P. Anticholinesterase agents In: Gilman AG, Goodman LS, Rall 
TW, Murad F eds. The pharmacological basis of therapeutics. New York: 
Mac Millan 1985; 110-129 
75 
 
 17. Mutalik GS, Wadia RS and Pai VR. Poisoning by diazinon an 
organophosphorous insecticide. Journal Of Indian medical association 1962; 
38:67-71. 
 18. Maroni M. Review of toxicological properties and biotransformation of 
organophosphorous esters. In : WHO Manual Of Analytical maethods. 
Cremona : WHO collaboration center for occupational health 1985 ; 3-39  
19. Hayes WJ. Organophosphorous insecticide. In : Hayes WJ, ed. 
Pesticides studied in man. Batlimore, Williams and Wilkins, 1982; 284-413 
 20. Karalliedde L, Organophosphorous poisoning and anesthesia, 
Anaesthesia 1999:54: 1073-1088 
. 21. Johnson MK. Inhibition, reactivation and aging of cholinesterases. 
Organophosphorous Winter meeting, Hannibal House, London, 1992 
 22. Davies DR, Green AL. The kinetics of reactivation by oximes of 
cholinesterase inhibition by Organophosphorous compounds. Biochemical 
Journal 1956;63: 529-535. 
 23. Johnson MK. Lauwerys R. Protection by some carbamates against the 
delayed neurotoxic effects of diesopropylphosphorofluoriddate. Nature 
1969; 222: 1066-1067. 
24. Moss DW, Hunderson DR, Kachmar JF, Exzymes. In: Tietz NW, ed. 
Textbook of clinical Chemistry. Philadelphia, WB Saunders Co; 1986: 619-
774.  
76 
 
25. Grob D, John RJ. Treatment of anticholinesterase intoxication with 
oximes. JAMA 1958; 166:1855  
26. Grob D, John RJ. Use of oximes in the treatment of intoxication by 
anticholinesterase compounds in normal subjects. American Journal of 
medicine 1953;24: 497-511.  
27. Garcia-Repetto R, Soria ML, Geminz MP, Menendez M, Repetto M. 
Deaths from pesticide poisoing in Spain from 1991 to 1996. Veterinary and 
Human Toxicology 1998; 40: 166-168.  
28. Senanayaje N, Karalliedde L. neurotoxic effects of Organophosphorous 
insecticide. NEJM 1987; 316, 716-763.  
29. Leon-S-Fidas E, Pradilla G. et el: Neurological effects of 
Organophosphorous pesticide. BMJ 1996 ; 313 : 690-691.  
30. Surjit singh and Sharma. Neurological syndromes following 
Organophosphorous poisoning. Neurology India 2000; 48: 308-313.  
31. Johnson MK, Lauwerys R. Protection by some carbamates against the 
delayed neurotoxic effects of diisoproylphosphoroflouride . Nature 1969; 
222: 1066-1067.  
32. Bidstrup PL, Bonnell JA, Beckett AG. Paralysis following poisoning by 
a new Organophosphorous insecticide( mipafox). BMJ 1953; 1:1068-1072.  
77 
 
33. Hiersons R, Johnson MK. Clinical and toxicological investigations of a 
case of delayed neuropathy in man after acute poisoning by an 
Organophosphorous pesticide. Archieves of Toxicology 1978; 40:279-284.  
34. Jederzyowsksa H, Rowinska-Marcincka K, Hoppe B. Neuropathy due to 
phtosol (Agritox) a report of a case. Acta Neuropathologica 1980; 49;163-
168.  
35. Senanyake N, Sanmuganathan PS. Extrapyramidal manifestations 
complicating Organ phosphorous insecticide poisoning. Human and 
experimental Toxicology 1995; 14: 600-604.  
36. Mingon A, Board P, Blackburn AC, Mellick GD, Le Counteur DG. 
Parkinsons disease, pesticide and Gluthathion transferase polymorphism. 
Lancet 1998;352: 1344-1346. 
37. Bellin JS, Chow I. Biochemical effects of chronic low level exposure 
topesticides. Research communications in chemical pathology and 
pharmacology 1974; 9:325-327.  
38. Casale GP, Cohen SD, Dicapua Ra. The effect of Organophosphorous 
induced cholinergic stimulation on the antibody response to sheep 
erythrocytes in inbred mice. Toxicology and Applied Pharmacology 1983; 
68:198-205.  
78 
 
 
39. Newcombe DS. Immune surveillance, Organophosphorous exposure and 
lymphoma genesis. Lancet 1992; 339:539-541.  
40. Murray VS, Wesiman HM, Dawling S, Morgan I, House IM. Health 
effects of Organ phosphorous sheep dips. BMJ 1992; 305: 1090.  
41. Cevin M, Leeb JE, Wishnow RM, et al. Effects of low-level 
administration of dichlorvas on adrenocorticotrophic hormone secretion, 
adrenal cholesteryl ester and steroid metabolism. Biochemical 
Pharmacology 1980; 29: 635-641. 
 42. Haubenstock A. More on the triad pf pancreatitits, hyperamylasemia 
and hyperglycemia. Journal of American Medical Assocition 1963; 249: 
1563. 
 43. Akthar N, Kayani SA, Ahmad MM, Shahab M. Insecticide induced 
changes in secretary activity of the thyroid glands in rats. Journal of applied 
pharmacology 1996; 16 :397-400. 44. Kiss Z, Fazekas T. 
Organophosphorous and Torsade de pointes ventricular tachycardia. Journal 
of the royal society of medicine 1983; 76: 984-985.  
45. Wren C, Carson PHM, Sanderson JM. Organophosphorous poisoning 
and complete heart block. Journal of royal society of medicine 1981; 
74;688-689.  
 
79 
 
46. Chuang FR, Jang SW, Lin JL, Chern MS, Chen JB, Hsu KT. QTc 
prolongation indicates a poor prognosis in patients with Organophosphorous 
poisoning. American journal of emergency medicine 1996; 14: 451-453.  
47. Gadoth N, Fisher A. Late onset of neuromuscular block in  
Organophosphorous poisoning. Annals of internal medicine 1978; 88: 654-
655.  
48. Hantson P, Hainaut P, Vander Stappen M, Mahieu p. Regulation of body 
temperature after acute Organophosphorous poisoning. Canadian journal of 
anaesthesia 1996; 43: 755.  
 
49. Thompson JW, Stocks RM. Brief bilateral vocal cord paralysis after 
insecticide poisoning: a new variant of toxicity syndrome. Archives of 
otolaryngology-head and neck surgery 1997; 123: 93-96.  
50. Fuller BH, Berger GMB. Automation of serum cholinesterase assay: 
pediatric and adult ranges. South African medical journal 1990; 78:577-580.  
51. Du toit PW, Muller Fo, Van Tonder WN, Ungerer MJ. Experience with 
the intensive care management of Organophosphorous insecticide 
poisoning. South African medical journal 1981; 60: 227-229.  
52. Taturi J, Roberts J. Organophosphorous poisoning. Annals of emergency 
medicine 1987; 16: 193-202.  
80 
 
53. Rumach BH. Anticholinergic poisoning. Treatment with physostigmine. 
Pediatrics 1973; 52: 449-551.  
54. .Mirakhur RK,Dundee JW. Glycopyrrolate: pharmacology. Anesthesia 
1983; 38: 1195-1203.  
55. Mc Cubbin TD, Brow JH, Dewar KMS, Jones LJ, SpenceAA. 
Glycopyrrolateas a premedicant. Comparison with atropine. British journal 
of anesthesia 1979; 51: 885-889. 
 56. Proakis AG, Harres GB. Comparative penetration of glycopyrrolate and 
atropine across the blood bran barrier in anesthetized dogs. Anesthesiology 
1978; 48: 339-344.  
57. Sedill FR, Groff Wa. Intramuscular and intravenous administration of 
smalldoes of Pyridine-2-aldoxime methyl chloride in man. Journal of 
pharmaceutical science 1971; 60: 1224-1228.  
58. Durham WF, Hayes WJ. Organophosphorous poisoning and its therapy. 
Achieves of environmental health 1962; 5: 21-47. 
 59. Johnson DD, Wibcox CW. Studies on the mechanism of protective and 
antidote actions of diazepam in Organophosphorous poisoning. European 
journal of pharmacology 1975; 34: 127-132.  
60. Lherman Y, Gutamn H. the use of respiratory stimulants in  
Organophosphorous intoxication. Medical hyothesis 1988; 26: 267-269.  
81 
 
 
61. Luzhniknov EA, Yaroslawsky AA, Molodenkov MN, Shurkalin BK, 
Ewsur NG, Barswkow UF. Plasma perfusion through charcoal in methyl 
parathion poisoning. Lancet 1977; 1: 38-39.  
62. Zweiner RJ, Ginsburg CM. Organophosphorous and carbamate 
poisoning in infants and children. Pediatrics 1988; 121-126.  
63. De Condole CA, Douglas WW, Evans CL, et al. The failure of 
respiration in death by anticholinesterase poisoning. British journal of 
pharmacology 1953; 8: 446-475. 
64. Goel A, S Joseph , Dutta TK. Organophosphate Poisoning: Predicting 
the need for ventilatory support. JAPI 1998; 46: 786-90  
65. G Avasthi, G Singh. Serval neuro-electrophysiological studies in acute 
Organophosphate Poisoning- correlation with clinical finding, serum 
cholinesterase levels and atropine dosages. JAPI 2000; 48(8): 794-799.  
66. Rousseau JM, Ruttimann M, Brinquin L. Acute Neurotoxic  
Organophosphorous poisoning: Insecticides and chemical weapons. Annales 
francaises d’anaesthesia et de Reanimation 2000; 19(8) : 588-98.  
67. Yamasheta M, et al. Human mortality in organophosphate Poisoning. 
Veterinary and human toxicology 1997; 39(2): 84-5  
68. Singh S, Sharma BK, Chug KS. Spectrum of acute poisoning in adults( 
20 years experience). JAPI 1984; 32(7): 561-563  
82 
 
69. M.Vishwanathan, K srinivasan. Poisoning by bug poison. A preliminary 
study. Journal of Indian Medical Association 1962, vol.39; No. 7: 345-349 
 70. OP Gupta, DD Pate. Diazinon poisoning: A study of 60 cases. JAPI 
July 1968; vol.16, No. 7 : 457-463  
71. Sarjit singh, Balkrishnana, Satwant Singh, Vinod Malhotra. Parathion 
poisoning in punjab (A clinical and electrocardiological study of 20 cases). 
JAPI 1969; 16:181-187  
72. Robert J, Zwiener, Charles M Ginsburg. Organophosphorous and 
carbamate poisoning in infants and children. Pediatrics 1988; 81:121-126  
73. Nouria S, Abroug F, Elatrous S, Boujdarin R. Prognostic value of 
serumcholinesterase in organophosphorous poisoning. Chest 1994; 
106:1811-1814.  
74. Kumar SS, Jayarajan A, Kuppaswamy G. continuous infusion of high 
dose of atropine in management of organophosphorous poisoning. JAPI 
1991; 39 190-193. 
 75. Karnik M, Wadia RS. Cholinesterase levels in diazion poisoning, 
relation to severity of poisoning. Japi 1970; 18;337-344.  
76. Bernard Rosner (2000), Fundamentals of Biostatistics, 5th Edition, 
Duxbury.  
77. M. Venkataswamy Reddy (2002), Statistics for Mental Health Care 
Research, NIMHANS publication, INDIA  
83 
 
PROFORMA 
PREDICTING THE NEED FOR VENTILATORY SUPPORT IN  
        ORGANOPHOSPHOROUS COMPOUND POISONING 
 
PARTICULARS OF THE PATIENT:   
                                                                          Case No: 
 Name : Hospital No. 
 Age :  
Sex :  
Address:  
                                                     Date of Admission:  
                                                     Date of discharge:  
Suicide/accidental  
Final Diagnosis: 
COMPLAINTS WITH DURATION  
- Time and date of consumption of Organophosphorous compound poison :  
- Compound 
 - Amount  
- Inhalation / Ingestion / Injection 
- Vomiting 
 - Altered sensorium  
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- Hyper salivation  
- Convulsion  
- Other Complaints  
- Referred from :  
Family History:  
Past History: 
Drug History:  
         Amino Glycosides  
         Chloroquine:  
Personal History:  
On Examination:  
Build  
Nourishment  
Wasting  
Pallor                                Cyanosis                                Icterus  
Lymphadenopathy           Clubbing                                 Edema  
Pulse:      
                                                     Breath Smell:  
B.P:                                               Tongue:  
R.R.: Skin:  
Temperature:  
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C.N.S  
Sensorium: Normal / Restleness / Drowsiness/Coma 
GCS: V E M =  
Pupils:  
Fasciculations: Total score  
 Anterior chest Posterior chest  
 Anterior abdomen Posterior abdomen  
 Right thigh Left thigh Right leg  
Left leg Right arm Left arm 
Weakness  
 Proximal muscle  
 Neck muscle  
 Respiratory muscle:  
 a) Single breath count:  
 b) Accessory muscle:  
xci 
c) Chest X-ray:  
P.A:  
C.V.S:  
DIAGNOSIS:  
Mild Poisoning / Moderate Poisoning / Severe Poisoning  
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Investigations: ABG – pH PCO2 PaO2  
 RBS Na+ K+ AST  
 ALT 
 SPO2  
 Management:  
Body wash:  
Stomach wash:  
Dose within the first 48 hrs Dose after 48 hrs after admission  
Atropine:  
P.A.M  
Fluids:  
Others:  
Intubation’s Hour after the consumption of O.P. Poisoning  
Ventilation: 
Those who developed intermediate syndrome:  
Those who developed complication Pneumonia  
 Pneumothorax:  
ICU Stay (Hrs)  
Hospital Stay (Hrs)  
OUTCOME: RECOVERED EXPIRED  
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ஆuni0BAF_uni0BCDவாளuni0BA9_uni0BCDைகெயாuni0BAA_uni0BCDபuni0BAE_uni0BCD: 
இடuni0BAE_uni0BCD:                                     
ேததி:   
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  PATIENT CONSENT FORM 
STUDY DETAIL: 
A PROSPECTIVE STUDY OF PREDICTIVE FACTORS FOR 
VENTILATORY SUPPORT IN OPC POISONING” 
STUDY CENTER: 
CHENGALPATTU MEDICAL COLLEGE & HOSPITAL, 
CHENGALPATTU 
 
PATIENT NAME:      PATIENT AGE: 
IDENTIFICATION NUMBER: 
I confirm that I have understood the purpose of procedure for the 
above study.  
I have the opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime without giving any reasons, without my 
legal rights being affected. 
I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
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respect to the current study and any further research that may be conducted 
in relation to it, even if withdraw from the study, I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from the study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperative with the study 
team and to immediately inform the study staff if I suffer from any 
deterioration in my health or wellbeing or any unexpected or unusual 
symptoms. 
I hereby give consent to participate in this study. 
I hereby give permission to undergo complete clinical examination 
and diagnostic test. 
 
Signature/Thumb impression:     Place:  
         Date: 
Patient name and address: 
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Sl.n
o 
Name Hospita
l no 
Age 
in yrs 
Sex 
M/
F 
Compound vomiyin
g 
F 
sco
re 
GCS 
Score 
Resp 
rate 
breat
h/mi
n 
Pulse 
rate 
beats/
min 
pupil 
size 
in 
mm 
O2 
sat 
in 
% 
Access 
muscle 
acting/not 
acting 
ABG 
PH 
ABG 
PCO2 
ABG 
PAO2 
TIME 
INTERV
AL 
In hrs 
Type of 
poisoning 
Atropin
e reqd 
with in 
48 
hrs(mg) 
Atropin
e reqd 
after 48 
hrs(mg) 
Patient 
ventilat
ed in 
hrs 
after 
cons.of 
opc 
ICU 
stay 
in hrs 
Hospi
tal 
stay 
in hrs 
complications Outcome   
1 RAGHU 257989 18 M Cypermethrine present 0 14 18 68 2 92 Not acting nil nil Nil 4 Mild  42.2 10 Nil  Nil  192 Nil  Recovered   
2 ARUN 249961 22 M Methyl 
parathion 
present 2 8 26 60 2 10
0 
In acting 7.1 64 45 8 Moderate  216 400 11 288 648 Nil  Recovered   
3 CHANDRASEKAR 21009 32 M Volphor absent 7 9  60 1 94 Not acting nil nil nil 8 Severe  180 154.6 Nil  Nil  216 Nil  Recovered   
4 LAKSHMI 19472 45 F Methyl 
parathion 
absent 0 12 22 70 2 96 Not acting nil nil nil 3 Mild  70 33.6 Nil  Nil  138 Nil  Recovered   
5 MARIYAPPAN 19522 40 M Betanechol PRESEN
T 
2 10 18 64 1 94 NOT 
ACTING 
NIL NIL NIL 6 Moderate  60 30 Nil  Nil  140 Nil  Recovered   
6 ANITHA 22041 22 F Monocrotophos present 4 10 16 54 1 92 Not acting nil nil nil 6 Severe  150 116.3 Nil  Nil  192 Nil  Recovered   
7 SASIKALA 271236 18 F Monocrotophos Absent 0 11 28 64 1 64 In action 7.2 56 60 10 Moderate  80 150 15 312 576 Pneumonia  Recovered   
8 NAGAPPAN 110023 20 M Monocrotophos present 3 14 18 68 2 96 Not acting Nil Nil  Nil  12 Mild  55.2 20 Nil  Nil  144 Nil  Recovered   
9 SEKAR 19898 15 M Triazophos  absent 0 14 16 84 3 97 Not acting Nil  Nil  Nil  8 Mild  50.6 40 Nil  Nil  166 Nil  Recovered   
10 PERUMAL 270681 25 M Methyl 
parathion 
present 4 15 24 74 2 78 In acting 7.1 44 58 8 Mild  60 160 28 160 360 Nil  Recovered   
11 MALAVI 14721 20 F Methyl 
parathion 
present 0 13 18 82 2 92 In acting Nil  Nil  Nil  4 Mild  72 50 Nil  Nil  144 Nil  Recovered   
12 NARAYANA 
SAMY 
248699 30 M Dimethoate  present 0 6 20 78 1 80 In acting 7.3 84 48 6 Severe  160 40.2 26 168 216 Pneumonia  Recovered   
13 PARAMESH 241109 16 M Methyl 
parathion 
present 5 9 30 64 1 94 In acting 7.24 70 48 8 Severe  198 250 10 208 214 Intermediate 
syndrome 
Expired   
14 NALLI 26670 28 M Dimethoate  present 4 6 24 64 1 70 In acting 7.12 68 45 6 Severe  86.4 40.2 28 168 216 Pneumonia  Recovered   
15 SUNITHA 199059 20 F Dimethoate  present 5 8 18 60 1 72 In acting 7.1 44 70 10 Mild  208 298 16 216 416 Pneumonia  Recovered   
16 ANJALI 234556 18 F Diazinon  absent 0 14 20 62 2 94 Not acting Nil  Nil  Nil  4 Mild  114.5 80.4 Nil  Nil  200 Nil  Recovered   
17 SAVITHA 264400 15 F Triazophos  absent 0 14 30 68 3 80 In acting 7.2 36 84 18 Mild  154 200 24 316 400 Nil  Recovered   
18 LAKSHMI 19904 38 F Dimethoate  present 0 13 24 72 2 94 Not acting Nil  Nil  Nil  8 Moderate  109 54.9 Nil  Nil  160 Nil  Recovered   
19 IMRAN 18890 44 M Betanechol present 1 10 28 72 1 96 Not acting Nil  Nil  Nil  2 Severe  98.6 88.6 Nil  Nil  208 Nil  Recovered   
20 JAGAN 258809 24 M Methyl 
parathion 
present 5 9 20 62 1 70 In acting 7.1 84  45 12 Severe  200 250 15 208 211 Intermediate 
syndrome 
Expired   
21 RAVI 233459 28 M Dimethoate  present 4 6 20 54 1 74 In acting 7.22 78 48 15 Severe  234.6 301.2 18 320 338 Pneumonai  Expired   
22 ANJAPPAN 25778 34 M Methyl 
parathion 
present 6 6 16 60 1 78 In acting 7.21 80 54 10 Moderate  140 156 16 200 216 Pneumonia  Recovered   
23 MAMITHA 244567 29 F Betanechol present 2 10 16 76 1 90 Not acting Nil  Nil  Nil  6 Moderate  109 109 Nil  Nil  198 Nil  Recovered   
24 MUTHULAKSH
MI 
14996 28 F Methyl 
parathion 
present 2 10 28 66 1 78 Not acting Nil  Nil  Nil  6 Severe  80 260 Nil  Nil  200 Nil  Recovered   
25 SRINIVAS 24090 29 M Monocrotophos present 6 6 40 64 1 70 In acting 7.2 84 50 12 Moderate  190 398.4 14 230 311 Pneumonia  Recovered   
26 ABDUL PASHA 14960 22 M Dimethoate  present 2 8 30 60 2 54 In acting 7.1  ` 74 46 8 Severe  244 244 9 302 303 Intermediate 
syndrome 
Expired  
27 SOMU 246001 32 M Dimethoate  present 7 9 20 70 1 95 Not acting Nil  Nil  Nil  5 Mild  198 240 Nil  Nil  200 Nil  Recovered   
28 GANESH 25999 35 M Methyl 
parathion 
absent 3 15 18 60 2 80 In acting 7.2 44 60 8 Moderate  198 100.8 20 199 402 Nil  Recovered   
29 RAJINI 12443 28 M Betanechol absent 1 10 34 70 1 97 Not acting Nil  Nil  Nil  8 Mild  158 30 Nil  Nil  289 Nil  Recovered   
30 MANJUNATH 24678 29 M Monocrotophos absent 3 14 36 64 2 96 Not acting Nil  Nil  Nil  16 Mild  78.8 33.5 Nil  Nil  188 Nil  Recovered   
31 GANESH 258998 15 M Triazophos  absent 0 14 18 72 3 93 Not acting Nil  Nil  Nil  10 Mild  60.4 30 Nil  Nil  200 Nil  Recovered   
32 JAGANATH 211066 29 M Methyl 
parathion 
present 4 15 28 80 2 94 Not acting Nil  Nil  Nil  10 Moderate  60 189.4 Nil  Nil  166 Nil  Recovered   
33 RAHIKA 23096 27 F Dimethoate  present 1 11 18 74 1 96 Not acting Nil  Nil  Nil  12 Moderate  160.7 100 Nil  Nil  260 Nil  Recovered   
34 GOPINATH 21105 18 M Dimethoate  present 1 10 20 68 1 95 Not acting Nil  Nil  Nil  6 Mild  140 60.7 Nil  Nil  238 Nil  Recovered   
35 ANATH 267709 29 M Cholpyrifos present 3 14 21 76 2 96 Not acting Nil  Nil  Nil  18 Mild  88.8 44.4 Nil  Nil  198 Nil  Recovered   
36 GUGAN 25546 23 M Quinophos  present 0 14 20 70 3 90 Not acting Nil  Nil  Nil  10 Mild  100 260 Nil  Nil  200 Nil  Recovered   
37 SUNDHARAM 23330 33 M Methyl 
parathion 
present 4 15 16 70 2 74 In acting 7.24 55 45 8 Moderate  60 198 32 160 240 Nil  Recovered   
38 RAGUNATH 28990 24 M Dimethoate  present 2 10 16 66 1 94 Not acting Nil  Nil  Nil  10 Mild  124 40.4 Nil  Nil  200 Nil  Recovered   
39 SIVA 199580 29 M Monocrotophos present 3 14 20 72 2 91 Not acting Nil  Nil  Nil  16 Mild  88.5 66.6 Nil  Nil  199 Nil  Recovered   
40 NARAYANAM
MA 
258069 28 F Triazophos  present 0 14 15 76 3 96 Not acting Nil  Nil  Nil  8 Mild  76.4 30 Nil  Nil  360 Nil  Recovered   
41 SIVAPRAKASH 259981 24 M Methyl 
parathion 
present 4 15 18 78 2 92 Not acting Nil  Nil  Nil  10 Moderate  80 109 Nil  Nil  144 Nil  Recovered   
42 DIPIKA 22009 33 F Dimethoate  present 2 110 22 64 1 94 Not acting Nil  Nil  Nil  10 Mild  111.3 40 Nil  Nil  140 Nil  Recovered   
43 MUNIAMMA 193661 30 F Quinolphos  present 2 14 18 68 2 95 Not acting Nil  Nil  Nil  8 Mild  56 60 Nil  Nil  192 Nil  Recovered   
44 AZEEMA 21023 29 F Triazophos  present 0 14 20 74 3 98 Not acting Nil  Nil  Nil  10 Mild  100.9 70 Nil  Nil  576 Nil  Recovered   
92 
 
45 SUDHAGAR 120003 25 M Dimethoate  present 4 15 18 70 2 74 In acting 7.1 68 50 15 Severe  60 300 36 250 489 Pneumonia  Recovered   
46 VENNILA 19622 24 F Monocrotophos present 0 13 22 72 2 92 Not acting Nil  Nil  Nil  4 Moderate  66.9 88 Nil  Nil  260 Nil  Recovered   
47 NAGARAJ 23042 28 M Methyl 
parathion 
present 2 10 18 64 1 94 Not acting Nil  Nil  Nil  6 Severe  90 43 Nil  Nil  201 Nil  Recovered   
48 SHARMILA 261231 22 F Monocrotophos present 4 10 16 50 4 90 Not acting Nil  Nil  Nil  12 Moderate  200 120.4 Nil  Nil  188 Nil  Recovered   
49 SUNDHARI 12100 28 F Dimethoate  present 3 11 26 60 3 64 Not acting 7.24 70 48 10 Moderate  199 264.3 15 312 360 Pneumonia  Recovered   
50 PASHA 17990 22 M Meta 
dimethoate 
present 2 8 22 60 2 78 Not acting 7.2 67 45 8 Moderate  216 360 11 300 240 Nil  Recovered   
51 SHANKAR 15734 45 M Methylparathion  present 2 11 22 78 1 96 Not acting Nil  Nil  Nil  10 Mild  42.4 10 Nil  Nil  192 Nil  Recovered   
52 KISHORE 24987 22 M Dimethoate  present 4 15 18 68 1 94 Not acting Nil  nil Nil  12 Mild  180 160.7 Nil  Nil  198 Nil  Recovered   
53 ETHIKA 24110 17 F Dimethoate  present 0 14 24 70 1 98 Not acting Nil  Nil  Nil  6 Mild  98 64 Nil  Nil  648 Nil  Recovered   
54 SATHANA 199023 23 F Methyl 
parathion 
present 2 8 28 60 2 74 In acting 7.1 64 45 8 Moderate  80 150 15 200 216 Pneumonia  Recovered   
55 VARMAN 29880 44 M Monocrotophos  present 1 13 16 66 1 98 Not acting Nil  Nil  Nil  6 Mild  108 117 Nil  Nil  140 Nil  Recovered   
56 PREETHIV 24421 21 M Dimethoate  present 1 14 20 68 1 94 Not acting Nil  Nil  Nil  8 Mild  208 298 Nil  Nil  144 Nil  Recovered   
57 RITHIKA 27600 15 F Monocrotophos  absent 0 11 28 64 1 64 In acting 7.2 56 60 10 Severe  190 240 28 168 214 Intermediate 
syndrome 
Expired    
58 BHUVANESH 26543 22 M Methylparathion  present 1 13 22 72 2 96 Not acting Nil  Nil  Nil  12 Mild  114.4 89 Nil  Nil  192 Nil  Recovered   
59 MALLIGA 299034 55 F Dimethoate  present 3 15 24 74 1 98 Not acting Nil  Nil  Nil  8 Mild  84 100 Nil  Nil  216 Nil  Recovered   
60 PANDIYAN 15998 43 M Methylparathio
n  
present 4 15 24 74 2 78 In acting 7.1 44 58 8 Moderate  80 44 26 312 576 Pneumonia  Recovered   
61 MENAKA 18897 28 F Dimethoate  present 0 14 18 70 1 96 Not acting Nil  Nil  Nil  4 Mild  200 98 Nil  Nil  311 Nil  Recovered   
62 DEEPAK 25887 19 M Dimethoate  present 5 9 30 64 1 64 In acting 7.24 70 48 6 Moderate  60 260 14 316 489 Pneumonia  Recovered   
63 RAJA 23246 40 M Monocrotophos  present 2 14 22 60 1 94 Not acting Nil  Nil  Nil  10 Mild  65 43 Nil  Nil  360 Nil  Recovered   
64 ARUN 17886 21 M Methylparathion  present 1 11 20 60 1 92 Not acting Nil  Nil  Nil  12 Mild  70 33.6 Nil  Nil  192 Nil  Recovered   
65 VASANTH 12343 30 M Dimethoate  present 5 8 28 62 1 70 In acting 7.12 68 45 6 Moderate  60 300 18 312 576 Pneumonia  Recovered   
66 DEEPA 24357 23 F Dimethoate  present 4 15 24 72 2 96 Not acting Nil  Nil  Nil  8 Mild  80 23 Nil  Nil  216 Nil  Recovered   
67 ANBU 14423 29 M Monocrotophos  present 3 15 20 62 1 94 Not acting Nil  Nil  Nil  12 Mild  72 50 Nil  Nil  214 Nil  Recovered   
68 SARAVANAN 32453 41 M Methyl 
parathion 
present 1 13 18 56 1 92 Not acting Nil  Nil  Nil  4 Mild  80 32 Nil  Nil  303 Nil  Recovered   
69 MEENAKSHI 18445 27 F Dimethoate  present 0 14 20 72 3 78 In acting 7.2 36 84 10 Severe  90 216 9 223 311 Pneumonia  Recovered   
70 RANI 27654 22 F Monocrotopos  present 1 11 22 78 1 96 Not acting Nil  Nil  Nil  8 Mild  98 43 Nil  Nil  338 Nil  Recovered   
71 PAVEESH 25200 21 M Dimethoate  present 1 10 18 72 1 90 Not acting Nil  Nil  Nil  10 Mild  64 94 Nil  Nil  198 Nil  Recovered   
72 RANJAN 23165 17 M Monocrotophos  present 1 14 22 66 1 92 Not acting Nil  Nil  Nil  6 Mild  109 56 Nil  Nil  169 Nil  Recovered   
73 SHEELA 76543 28 F Meta 
dimethoate  
present 2 8 24 60 2 78 In acting 7.2 67 45 8 Moderate  111 109 20 230 311 Pneumonia  Recovered   
74 PUGHAL 87690 34 M Methyl 
parathion  
present 3 15 28 70 2 80 In acting 7.0 74 46 8 Moderate  60 260 15 302 303 Pneumonia  Recovered   
75 VINOTH 45321 22 M Methylparathion  present 0 15 20 78 1 98 Not acting Nil  Nil  Nil  4 Mild  98 88 Nil  Nil  144 Nil  Recovered   
76 RAJ 87651 26 M Methylparathion  present 4 11 18 64 1 98 Not acting Nil  Nil  Nil  6 Mild  182 40 Nil  Nil  189 Nil  Recovered   
77 KAMAL 187451 60 M Volphor  present 2 10 16 62 1 96 Not acting Nil  Nil  Nil  14 Mild  180 132 Nil  Nil  199 Nil  Recovered   
78 SNEGAN 32567 42 M Triazophos  present 0 14 20 72 3 80 In acting 7.1 44 70 10 Moderate  154 200 26 168 216 Pneumonia  Recovered   
79 SANJAY 211451 30 M Dimethoate  present 1 13 22 58 2 94 Not acting Nil  Nil  Nil  8 Mild  80 150 Nil  Nil  200 Nil  Recovered   
80 ANITHA 256732 26 F Monocrotophos  present 1 14 18 78 1 96 Not acting Nil  Nil  Nil  10 Mild  68 46 Nil  Nil  230 Nil  Recovered   
81 GOWRI 98123 18 F Methylparathio
n  
present 4 15 26 74 2 78 In acting 7.0 44 58 8 Mild  198 240 18 320 338 Pneumonia  Recovered   
82 KANDASAMY 28004 55 M Dimethoate  present 0 15 24 74 3 92 Not acting Nil  Nil  Nil  12 Mild  72 50 Nil  Nil  208 Nil  Recovered   
83 NATHAN 87123 44 M Dimethoate  present 6 6 30 76 1 78 In acting 7.12 78 48 15 Moderate  124 160 36 168 216 Pneumonia  Recovered   
84 SHIVA 34215 19 M Dimethoate  Present  4 6 40 60 1 74 In acting 7.24 80 54 10 Severe  90 40 Nil  312 576 Pneumonia  Recovered   
85 JEEVITHA 90456 24 F Methlyparathion  present 3 11 28 60 1 64 In acting 7.1 70 46 10 Severe  244 380 9 322 360 Intermediate 
syndrome 
Expired   
86 KANNAN 34123 38 M Quinophos  present 2 10 22 66 2 94 Not acting Nil  Nil  Nil  12 Mild  60.5 28 Nil  Nil  238 Nil  Recovered   
87 KAVERI 187690 33 F Cholpyrifos  present 1 11 18 78 1 96 Not acting Nil  Nil  Nil  14 Mild  88.2 40 Nil  Nil  200 Nil  Recovered   
88 SHANTHI 231421 20 F Dimethoate  Present  5 9 30 64 1 64 In acting 7.3 84 48 6 Severe   200 250 16 312 576 Pneumonia  Expired   
89 SATHYA 14523 25 F Betanechol  present 1 14 24 68 1 98 Not acting Nil  Nil  Nil  16 Mild  55.2 40 Nil  Nil  192 Nil  Recovered   
90 JEYARAM 213420 47 M Dimethoate  present 1 13 22 72 2 92 Not acting Nil  Nil  Nil  8 Mild  109.2 54 Nil  Nil  240 Nil  Recovered   
91 PRAVEEN 23189 17 M Dimethoate  Present  7 9 26 60 1 70 In acting 7.1 74 46 12 Moderate  208 298 15 230 311 Intermediate syndrome Expired   
92 MANI 234210 20 M Betanachol  present 0 10 20 76 1 96 Not acting Nil  Nil  Nil  10 Mild  98.2 76.8 Nil  Nil  188 Nil  Recovered   
93 MEGALA 17823 23 F Methylparathion  Absent  3 15 28 70 2 80 In acting 7.2 44 60 8 Moderate  90 216 32 200 210 Pneumonia  Recovered   
94 KUPPUSAMY 23124 50 M Dimethoate  present 1 10 22 64 2 96 Not acting Nil  Nil  Nil  10 Mild  109 54 Nil  Nil  192 Nil  Recovered   
95 VIJAYA 19898 34 F Methylparathion  present 2 14 18 78 3 96 Not acting Nil  Nil  Nil  12 Mild  80 108 Nil  Nil  140 Nil  Recovered   
96 ATCHAYA 234454 18 F Dimethoate  present 0 14 20 64 1 98 Not acting Nil  Nil  Nil  10 Mild  60 30 Nil  Nil  289 Nil  Recovered   
97 PAKRISAMY 23423 35 M Betanechol  Absent  4  
13 
16 72 1 94 Not acting Nil  Nil  Nil  8 Mild  56 40 Nil  Nil  489 Nil  Recovered   
98 SUBRAMANI 24098 45 M Methylparathion  Present  4 15 18 68 2 74 In acting 7.24 55 45 8 Moderate  60 300 20 160 360 Pneumonia  Recovered   
99 INDIRANI 27900 40 F Dimethoate  present 4 15 26 70 2 74 In acting 7.1 68 50 15 Severe  200 128 15 Nil  200 Pneumonia  Recovered   
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